Evidence map›Paper›PMID 40124418›Full record

ArticleDegenerative neurological and neuromuscular disease2025

A Hypothesized Therapeutic Role of (Z)-Endoxifen in Duchenne Muscular Dystrophy (DMD).

H Lawrence Remmel, Sandra S Hammer, Laurence A Neff, Olivier M Dorchies, Leonardo Scapozza, Dirk Fischer, Steven C Quay

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Degenerative neurological and neuromuscular disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

H Lawrence RemmelAtossa Therapeutics, Inc., Seattle, WA, USA.ORCID 0000-0002-5742-829X
Sandra S HammerAtossa Therapeutics, Inc., Seattle, WA, USA.ORCID 0009-0003-7760-4582
Laurence A NeffSchool of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-4472-8453
Olivier M DorchiesSchool of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.ORCID 0000-0002-6665-7887
Leonardo ScapozzaSchool of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.ORCID 0000-0003-1079-648X
Dirk FischerDivision of Pediatric Neurology and Developmental Medicine, University Children's Hospital Basel (UKBB), University of Basel, Basel, Switzerland.
Steven C QuayAtossa Therapeutics, Inc., Seattle, WA, USA.ORCID 0000-0002-0363-7651

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Duchenne Muscular Dystrophy (DMD) is an inherited, X-linked disorder that is progressive, debilitating, and ultimately fatal. The current therapeutic landscape offers no cures, but does include palliative treatments that delay disease progression, and there is progress on genetic therapies that have the promise to be curative. There is much room for new therapies, and foundational work with the estrogen receptor modulator tamoxifen suggests the potential of a unique spectrum of therapeutic benefit from endoxifen, a metabolite of tamoxifen. Here we describe the potential for this new DMD therapy in the context of the overall DMD therapeutic landscape.

Indexed as

DMD carrier associated pathologiesDuchenne Muscular DystrophyEndoxifenestrogenprotein kinase Crepurposed therapy

Identifiers

PMID40124418
PMCPMC11923445

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.